JP2015508092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508092A5 JP2015508092A5 JP2014558118A JP2014558118A JP2015508092A5 JP 2015508092 A5 JP2015508092 A5 JP 2015508092A5 JP 2014558118 A JP2014558118 A JP 2014558118A JP 2014558118 A JP2014558118 A JP 2014558118A JP 2015508092 A5 JP2015508092 A5 JP 2015508092A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- compound according
- alkyl group
- condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010065687 Bone loss Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 238000004166 bioassay Methods 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 150000002540 isothiocyanates Chemical class 0.000 claims 1
- 208000011661 metabolic syndrome X Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382066 | 2012-02-24 | ||
| EP12382066.4 | 2012-02-24 | ||
| PCT/EP2013/053554 WO2013124413A1 (en) | 2012-02-24 | 2013-02-22 | Thiadiazolidinediones as gsk-3 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000211A Division JP6518270B2 (ja) | 2012-02-24 | 2017-01-04 | Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508092A JP2015508092A (ja) | 2015-03-16 |
| JP2015508092A5 true JP2015508092A5 (cg-RX-API-DMAC10.html) | 2015-10-15 |
| JP6073377B2 JP6073377B2 (ja) | 2017-02-01 |
Family
ID=47747639
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558118A Active JP6073377B2 (ja) | 2012-02-24 | 2013-02-22 | Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン |
| JP2017000211A Active JP6518270B2 (ja) | 2012-02-24 | 2017-01-04 | Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000211A Active JP6518270B2 (ja) | 2012-02-24 | 2017-01-04 | Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン |
Country Status (18)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2865351C (en) | 2012-02-24 | 2019-08-20 | Asd Therapeutics Partners Llc | Thiadiazolidinediones as gsk-3 inhibitors |
| RS60371B1 (sr) | 2013-03-14 | 2020-07-31 | Brigham & Womens Hospital Inc | Sastavi i postupci za ekspanziju i kultivisanje epitelnih matičnih ćelija |
| KR102567244B1 (ko) * | 2014-06-12 | 2023-08-16 | 세다르스-신나이 메디칼 센터 | 암을 치료하는 조성물 및 방법 |
| CN107073042A (zh) | 2014-09-03 | 2017-08-18 | 布里格海姆妇女医院公司 | 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法 |
| CA3010610A1 (en) | 2016-01-08 | 2017-07-13 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US11066419B2 (en) | 2016-12-30 | 2021-07-20 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using same |
| EP3837351A1 (en) | 2018-08-17 | 2021-06-23 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
| CA3109647A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
| DK3867711T3 (da) * | 2018-10-16 | 2024-03-11 | Italia Tech Alliance S R L | Viklemaskine med evalueringssystem til vævsmateriale som behandles og fremgangsmåde |
| WO2020163812A1 (en) | 2019-02-08 | 2020-08-13 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| WO2022170437A1 (en) * | 2021-02-11 | 2022-08-18 | Venca Research, Inc. | Compositions and methods for treating arrhythmogenic cardiomyopathy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
| PL209780B1 (pl) * | 2000-05-11 | 2011-10-31 | Consejo Superior Investigacion | Zastosowanie pochodnych tiadiazolidynodionu do wytwarzania leku |
| EP1586318A1 (en) * | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
| KR100837785B1 (ko) * | 2007-01-17 | 2008-06-13 | 한국화학연구원 | 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물 |
| CA2865351C (en) | 2012-02-24 | 2019-08-20 | Asd Therapeutics Partners Llc | Thiadiazolidinediones as gsk-3 inhibitors |
-
2013
- 2013-02-22 CA CA2865351A patent/CA2865351C/en active Active
- 2013-02-22 WO PCT/EP2013/053554 patent/WO2013124413A1/en not_active Ceased
- 2013-02-22 AU AU2013224041A patent/AU2013224041B2/en active Active
- 2013-02-22 SI SI201330704T patent/SI2838888T1/sl unknown
- 2013-02-22 US US14/380,623 patent/US9371299B2/en active Active
- 2013-02-22 HR HRP20170964TT patent/HRP20170964T1/hr unknown
- 2013-02-22 ES ES13705492.0T patent/ES2632428T3/es active Active
- 2013-02-22 DK DK13705492.0T patent/DK2838888T3/en active
- 2013-02-22 JP JP2014558118A patent/JP6073377B2/ja active Active
- 2013-02-22 EP EP13705492.0A patent/EP2838888B1/en active Active
- 2013-02-22 PT PT137054920T patent/PT2838888T/pt unknown
- 2013-02-22 NZ NZ630615A patent/NZ630615A/en unknown
- 2013-02-22 HU HUE13705492A patent/HUE035089T2/hu unknown
- 2013-02-22 LT LTEP13705492.0T patent/LT2838888T/lt unknown
- 2013-02-22 PL PL13705492T patent/PL2838888T3/pl unknown
- 2013-02-22 IN IN7885DEN2014 patent/IN2014DN07885A/en unknown
-
2014
- 2014-08-25 ZA ZA2014/06225A patent/ZA201406225B/en unknown
-
2016
- 2016-05-16 US US15/155,437 patent/US9469618B2/en active Active
-
2017
- 2017-01-04 JP JP2017000211A patent/JP6518270B2/ja active Active
- 2017-07-12 CY CY20171100737T patent/CY1119231T1/el unknown
- 2017-10-20 AU AU2017248556A patent/AU2017248556B2/en active Active